Estados financieros detallados de AEON Biopharma, Inc. (AEON): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $0.26, AEON presenta beneficios negativos (P/E no significativo) y un ROE del 204.18%. La capitalización bursátil es de $11M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | $3.4M | $2.5M | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $3.4M | $2.5M | 0 | 0 | 0 | 0 | 0 |
| I+D | $4.8M | $7.3M | $25.7M | $34.8M | $33.0M | $14.2M | $4.1M |
| Generales y Administrativos | $46.0M | $11.6M | $11.2M | $13.7M | $19.8M | $13.6M | $12.2M |
| Gastos Operativos | $57.3M | $18.9M | $65.8M | $48.4M | $348.1M | -$73.0M | $12.8M |
| Beneficio Operativo | -$54.0M | -$16.4M | -$65.8M | -$48.4M | -$348.1M | $73.0M | -$12.8M |
| EBITDA | -$47.5M | -$15.5M | -$36.9M | -$52.5M | -$52.7M | -$27.7M | -$16.2M |
| Gastos por Intereses | $7.5M | $15000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | $145.7M | -$32.9M | -$55.6M | -$52.6M | -$384.6M | $42.0M | -$39.2M |
| Impuestos | $14.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | $172.9M | -$32.9M | -$55.6M | -$52.6M | -$384.6M | $42.0M | -$39.2M |
| BPA | $1481.04 | $-0.01 | $18.86 | $-27.25 | $-744.83 | $77.74 | $-3.95 |
| BPA Diluido | $1481.04 | $-0.01 | $18.86 | $-27.25 | $-744.83 | $72.93 | $-3.95 |
| Acciones en Circulación (Diluidas) | $92301 | $479166 | $434805 | $1.9M | $516399 | $575940 | $9.9M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $6.3M | $20.2M | $5.1M | $9.7M | $5.2M | $13000 | $3.0M |
| Inversiones a Corto | $105.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $267000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $112.1M | $20.4M | $5.2M | $9.8M | $6.2M | $1.6M | $3.4M |
| Inmovilizado Material | 0 | 0 | $922000 | $906000 | $594000 | $1.5M | $1.2M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $114.4M | $21.2M | $6.4M | $10.8M | $6.8M | $3.1M | $5.6M |
| Cuentas por Pagar | $1.0M | $2.0M | $1.2M | $7.8M | $3.4M | $5.9M | $942000 |
| Deuda a Corto | $14.8M | 0 | $15.6M | $70.9M | 0 | 0 | 0 |
| Pasivos Corrientes | $17.5M | $4.2M | $20.8M | $82.6M | $13.0M | $14.1M | $6.9M |
| Deuda a Largo | $15.2M | $72.2M | $70.8M | $60.4M | 0 | $11.7M | $34.6M |
| Pasivos Totales | $180.2M | $224.4M | $230.3M | $281.2M | $159.9M | $31.7M | $60.6M |
| Reservas | -$333.7M | -$366.6M | -$422.3M | -$474.8M | -$473.6M | -$431.6M | -$470.8M |
| Patrimonio Neto | -$67.2M | -$208.3M | -$234.9M | -$287.5M | -$153.0M | -$28.6M | -$55.0M |
| Deuda Total | $30.0M | $72.2M | $86.9M | $131.5M | $278000 | $13.0M | $35.7M |
| Deuda Neta | -$81.8M | $52.0M | $81.8M | $121.8M | -$4.9M | $12.9M | $32.7M |
| Capital Circulante | $94.7M | $16.2M | -$15.7M | -$72.7M | -$6.8M | -$12.6M | -$3.5M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | $160.3M | -$32.9M | -$55.6M | -$52.6M | -$384.6M | $42.0M | -$39.2M |
| Amortizaciones | $1.3M | 0 | $3000 | $68000 | $99000 | $97000 | $78000 |
| Compensación en Acciones | $5.3M | $4.8M | $5.2M | $5.9M | 0 | $6.2M | $5.3M |
| Cambio en Capital Circulante | $50000 | $1.5M | $1.4M | $6.3M | -$2.7M | $706000 | -$6.9M |
| Flujo de Caja Operativo | -$44.7M | -$9.5M | -$28.4M | -$35.6M | -$47.8M | -$20.3M | -$17.3M |
| Inversiones (CapEx) | -$1.7M | 0 | -$170000 | -$306000 | 0 | 0 | -$4000 |
| Adquisiciones | -$36.5M | -$1.3M | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | -$64000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$46.4M | -$9.5M | -$28.6M | -$35.9M | -$47.8M | -$20.3M | -$17.3M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -25.0% | -100.0% | |||||
| Crecimiento Beneficio Neto (anual) | -119.0% | -69.0% | +5.5% | -631.9% | +110.9% | -193.4% | |
| Crecimiento BPA (anual) | -100.0% | +262044.4% | -244.5% | -2633.3% | +110.4% | -105.1% | |
| Cambio en Acciones (anual) | +419.1% | -9.3% | +343.5% | -73.2% | +11.5% | +1622.7% | |
| Crecimiento FCF (anual) | +79.6% | -202.3% | -25.5% | -33.3% | +57.6% | +14.7% | |
| Margen Bruto | 100.0% | 100.0% | |||||
| Margen Operativo | -1607.6% | -650.8% | |||||
| Margen EBITDA | -1414.8% | -616.1% | |||||
| Margen Neto | 5151.0% | -1307.1% | |||||
| Margen FCF | -1382.8% | -375.7% | |||||
| Tasa Impositiva Efectiva | 10.1% | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-502.91 | $-19.74 | $-65.78 | $-18.61 | $-92.61 | $-35.23 | $-1.74 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $92301 | $479166 | $434805 | $1.9M | $516399 | $540355 | $9.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 204.18% |
| Rentabilidad sobre capital invertido | 1699.74% |
| Rentabilidad sobre activos | -924.25% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | -0.18 |
| Ratio corriente | 0.54 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -126.80 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | 0.45 | -92000.00 | 35.12 | -24.31 | -0.70 | 0.50 | -0.28 |
| P/VC | -0.91 | -1.52 | -1.23 | -4.44 | -1.75 | -0.74 | -0.20 |
| P/V | 18.21 | 126.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | -1607.6% | -650.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 5151.0% | -1307.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ABP · APM · BOLT · CING · CLNN · CLRB · LYRA
Explorar sector: Healthcare · Biotechnology
Más secciones de AEON: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones